fda warning letters compounded semaglutide november 2025 Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control FDA Issues Warning Letters to
Description
A higher dose can worsen appetite suppression, making it harder to meet your nutrition needs

Use your time on medication to build habits thatll serve you whether you stay on the drug or not: Find physical activities you actually enjoy (not just what you think you should do) Work with a nutritionist to learn sustainable eating patterns (in my practice, we provide complimentary personalized nutrition plans to help patients maximize their GLP-1 results and build lasting habits) Tackle emotional eating with a therapist if needed Build your support network Your Personal Risk Factors Your individual situation matters enormously: Diabetes : You might need to stay on for blood sugar control regardless of weight Heart disease : These medications protect your cardiovascular system beyond weight loss Sleep apnea : Weight regain can make this dangerous condition worse Mental health : Some people experience better mood and eating behaviors on these medications Questions You Should Ask Yourself Before making any decisions about stopping or continuing, think about: What do I really want to achieve
Patients were matched in a 1:1 ratio using the nearest neighbor matching algorithm, with a caliper width of 0.2 standard deviations of the logit of the propensity score

Mounjaro at 15 mg produces an average weight loss of 22.5% in trials, and Wegovy at 7.2 mg produces 20.7% 8,9
